Gupta, N., Wang, X., Offman, E., Rich, B., Kerstein, D., Hanley, M., . . . Venkatakrishnan, K. (2020). Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study. CPT Pharmacometrics Syst Pharmacol.
シカゴスタイル引用形Gupta, Neeraj, Xiaohui Wang, Elliot Offman, Benjamin Rich, David Kerstein, Michael Hanley, Paul M. Diderichsen, Pingkuan Zhang, , Karthik Venkatakrishnan. "Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study." CPT Pharmacometrics Syst Pharmacol 2020.
MLA引用形式Gupta, Neeraj, et al. "Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study." CPT Pharmacometrics Syst Pharmacol 2020.